NCT04524962View on ClinicalTrials.gov

Study of Descartes-30 in Acute Respiratory Distress Syndrome

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2023

Conditions
Acute Respiratory Distress SyndromeCovid19
Interventions
BIOLOGICAL

Descartes 30

Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.

Trial Locations (2)

21201

University of Maryland Medical Center Medical Center, Baltimore

52242

University of Iowa Hospitals and Clinics, Iowa City

Sponsors
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Cartesian Therapeutics

INDUSTRY